Allergy & Immunology
Sonelokimab: A Promising Dual IL-17A/F Nanobody for Moderate-to-Severe Hidradenitis Suppurativa
The phase 2 MIRA trial shows sonelokimab, an IL-17A/F-inhibiting nanobody, significantly improves outcomes in moderate-to-severe hidradenitis suppurativa with good tolerability compared to placebo.
